NOT-HL-17-537: Notice of Availability of Frequently Asked Questions for RFA-HL-18-018 "Preparing for Hybrid Effectiveness-Implementation Trials for Heart, Lung, Blood, and Sleep Diseases in the Inpatient Setting (U01)"

Notice of Availability of Frequently Asked Questions for RFA-HL-18-018 "Preparing for Hybrid Effectiveness-Implementation Trials for Heart, Lung, Blood, and Sleep Diseases in the Inpatient Setting (U01)"

Notice Number: NOT-HL-17-537

Key Dates
Release Date: August 28, 2017

Related Announcements
RFA-HL-18-018

Issued by
National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform potential applicants that NHLBI has posted a set of answers to Frequently Asked Questions (FAQs) regarding applications for RFA-HL-18-018, "Preparing for Hybrid Effectiveness-Implementation Trials for Heart, Lung, Blood, and Sleep Diseases in the Inpatient Setting (U01)".

The FAQs are available at this site:

https://www.nhlbi.nih.gov/research/funding/faq-rfa-hl-18-018

While not required, all applicants are encouraged to view the FAQs prior to submitting their application.

Inquiries

Please direct all inquiries to:

Lora Reineck, M.D., M.S.
Division of Lung Diseases
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0222
Email: [email protected]

Catherine Stoney, Ph.D.
Division of Cardiovascular Sciences
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-6670
Email: [email protected]

Cheryl Boyce, Ph.D.
Center for Translation Research and Implementation Science
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-496-1051
Email: [email protected]

Andrei Kindzelski, M.D., Ph.D.
Division of Blood Diseases and Resources
National Heart, Lung and Blood Institute (NHLBI)
Telephone: 301-435-0050
Email: [email protected]